Year: 2026
Type: article
Abstract: Lipid nanoparticles (LNPs) are the most clinically advanced and efficient method for delivering messenger RNA (mRNA), with most studies focusing on cancer mRNA vaccines and prophylactic mRNA vaccines against infectious diseases.1 Recent developments in this field have prompted researchers to explore the applicability of this platform toward additional therapies, such as mRNA-encoded antibody therapy.2 Unlike conventional recombinant antibody therapy, which is considered time-consuming and labor intensive, mRNA-encoded antibody therapy is faster, simpler, and more scalable.
Authors: Ofer Cohen, Uri Elia
Institution: Israel Institute for Biological Research
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7234901120
